antiarrhythmic/脳卒中

Background: Atrial fibrillation (AF) is the most common arrhythmia in clinical practice with a prevalence of 2-3 percent in the population. Catheter ablation performing pulmonary vein isolation (PVI) is an established treatment, which aim to eliminate triggers from the pulmonary veins. This

This study involves participants from the randomised clinical trial which was just completed (CASA AF RCT: NCT02755688; ISRCTN18250790 ). They have undergone relevant ablation procedures in a randomised fashion and completed 12 months follow up. At the last study visit they signed a consent form to

The aim of this study is to compare 2 approaches for AF treatment, endocardial catheter isolation of the pulmonary veins (PV) versus minimally invasive thoracoscopic surgical epicardial ablation. The patients in both groups will be comparable and have persistant or LSP AF only. Patients with

Cardiovascular diseases are the leading cause of morbidity and mortality in diabetic patients. New hypoglycemic drugs are required to undergo cardiovascular safety studies for their release. In 2015, EMPA-REG OUTCOME, which was done for empagliflozin´s approval was the first study to provide

Background: Atrial fibrillation (AF) is the most commonly encountered clinical arrhythmia. Symptoms arising from AF are common, and may include palpitations, fatigue, exertional intolerance, and angina. Relief of symptoms is achieved by rhythm control strategies including drug therapy and catheter

Botulinium toxin use has been developed with success in wide-ranging fields (neurology, otorhinolaryngology, gynaecology, urology, plastic surgery, pain therapy), but not in cardiology. In the cardio-vascular field, only one pilot study on man has shown its utility in the prevention of atrial

There are an estimated 1.4 million people in the UK with atrial fibrillation (AF), which accounts for 2.4% of the adult population.1 It is well established that AF is a major causative factor for ischaemic stroke and systemic embolism.2 In addition, strokes resulting from AF carry the highest

INTRODUCTION Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, having a prevalence of about ~ 2% in the general population. Among healthy men and women age 40 years, the risk of lifelong AF occurrence is approximately 25%. The current estimated prevalence of AF is

Aim of the study The aim of this work is to study the effect of preoperative Colchicine, Dronedarone or Amiodarone for prophylaxis against postoperative atrial fibrillation in patients undergoing on-pump CABG. Patients and Methods Type and site of the study: This randomized double blinded clinical

After adequate stroke prevention (e.g. anticoagulation) and rate control, the optimum strategy for patients who continue to be symptomatic with persistent AF has not been established. Cardioversion with antiarrhythmic medication is commonly used as a first-line rhythm control strategy despite very

The study was conducted at The Cardiothoracic surgery intensive care unit of Ain Shams University hospitals during a period of 6 months. The study protocol was approved by "research and ethics committee" of anesthesia and intensive care department, Ain Shams University. Informative consent was

Cardiac arrythmias are the most common cardiac complications after thoracic surgery. They are made primarily of postoperative atrial fibrillation (POAF). They are associated with an increased risk of stroke, increased length of hospital stay and cost of care, and increased long-term

Atrial arrhythmias are very common and widespread. Recent reports suggest that 9% of patients over the age of 65 currently have atrial fibrillation. In individuals of European descent the lifetime risk of atrial fibrillation is as high as 26%. Atrial fibrillation carries significant risk of

Atrial Fibrillation Epidemic and the Need for Improved Therapies: Atrial fibrillation (AF) has become a disease of global epidemic proportions due to the burgeoning population of elderly individuals. The global burden of AF was recently estimated at 33.5 million with progressive increases in